keyword
MENU ▼
Read by QxMD icon Read
search

Cancer pain, neuropathy, pain

keyword
https://www.readbyqxmd.com/read/28505604/nrf2-and-nf-%C3%AE%C2%BAb-modulation-by-plumbagin-attenuates-functional-behavioural-and-biochemical-deficits-in-rat-model-of-neuropathic-pain
#1
Vijay Arruri, Prashanth Komirishetty, Aparna Areti, Siva Kumar Naik Dungavath, Ashutosh Kumar
BACKGROUND: Plumbagin is known to exhibit a broad range of biological activities including anti-cancer, antimicrobial and has been widely used traditionally. Nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) inhibitory and Nuclear factor (erythroid derived-2) like-2 (Nrf2) modulatory activities of Plumbagin have been reported already. In nerve injury model of neuropathy in rats, the role of NF-κB upregulation and declined antioxidant defence has been well recognized...
February 27, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28495639/safety-and-tolerability-of-the-first-in-class-agent-cpi-613-in-combination-with-modified-folfirinox-in-patients-with-metastatic-pancreatic-cancer-a-single-centre-open-label-dose-escalation-phase-1-trial
#2
Angela Alistar, Bonny B Morris, Rodwige Desnoyer, Heidi D Klepin, Keyanoosh Hosseinzadeh, Clancy Clark, Amy Cameron, John Leyendecker, Ralph D'Agostino, Umit Topaloglu, Lakmal W Boteju, Asela R Boteju, Rob Shorr, Zuzana Zachar, Paul M Bingham, Tamjeed Ahmed, Sandrine Crane, Riddhishkumar Shah, John J Migliano, Timothy S Pardee, Lance Miller, Gregory Hawkins, Guangxu Jin, Wei Zhang, Boris Pasche
BACKGROUND: Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%, and more than 50% of patients presenting with metastatic disease. Metabolic reprogramming is an emerging hallmark of pancreatic adenocarcinoma. CPI-613 is a novel anticancer agent that selectively targets the altered form of mitochondrial energy metabolism in tumour cells, causing changes in mitochondrial enzyme activities and redox status that lead to apoptosis, necrosis, and autophagy of tumour cells...
May 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28486769/chemotherapy-induced-peripheral-neuropathy-a-current-review
#3
REVIEW
Nathan P Staff, Anna Grisold, Wolfgang Grisold, Anthony J Windebank
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30-40% of patients treated with neurotoxic chemotherapy will develop CIPN and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents...
May 9, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28458631/inhibition-of-mitochondrial-p53-accumulation-by-pft-%C3%AE-prevents-cisplatin-induced-peripheral-neuropathy
#4
Magdalena A Maj, Jiacheng Ma, Karen N Krukowski, Annemieke Kavelaars, Cobi J Heijnen
Chemotherapy-induced peripheral neuropathy (CIPN), a debilitating major side effect of cancer treatment, is characterized by pain and sensory loss in hand and feet. Platinum-based chemotherapeutics like cisplatin frequently induce CIPN. The molecular mechanism underlying these neurotoxic symptoms is incompletely understood and there are no preventive or curative interventions. We hypothesized that cisplatin acts as a cellular stressor that triggers p53 accumulation at mitochondria, leading to mitochondrial dysfunction and CIPN...
2017: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/28451384/chemotherapy-induced-peripheral-neuropathy
#5
Xia Zhang, Wei-Wei Chen, Wen-Juan Huang
Neuropathy is associated with side effects of frontline chemotherapeutics, which is a prominent therapy utilized in prevalent cancers. Peripheral neuropathy negatively impacts quality of life in cancer patients and survivors. It also affects the dose plan of the treatment, thereby limiting the efficacy of the treatment. We searched the electronic database PubMed for pre-clinically and clinically controlled trials reporting neuropathy of adverse effects, a result of chemotherapy in cancer patients. It was observed clearly that many reports provide clinical evidence to rapidly growing neuropathy cases of cancer patients...
March 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28436999/clinical-practice-guidelines-on-the-evidence-based-use-of-integrative-therapies-during-and-after-breast-cancer-treatment
#6
REVIEW
Heather Greenlee, Melissa J DuPont-Reyes, Lynda G Balneaves, Linda E Carlson, Misha R Cohen, Gary Deng, Jillian A Johnson, Matthew Mumber, Dugald Seely, Suzanna M Zick, Lindsay M Boyce, Debu Tripathy
Answer questions and earn CME/CNE Patients with breast cancer commonly use complementary and integrative therapies as supportive care during cancer treatment and to manage treatment-related side effects. However, evidence supporting the use of such therapies in the oncology setting is limited. This report provides updated clinical practice guidelines from the Society for Integrative Oncology on the use of integrative therapies for specific clinical indications during and after breast cancer treatment, including anxiety/stress, depression/mood disorders, fatigue, quality of life/physical functioning, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance...
April 24, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28430016/the-use-of-intravenous-lidocaine-for-the-management-of-acute-pain-secondary-to-traumatic-ankle-injury
#7
Billy Sin, Diana Gritsenko, Grace Tam, Kimberly Koop, Eva Mok
Sports-related injuries are a frequent cause of visits to the emergency department (ED) across the United States. A majority of these injuries affect the lower extremities with the ankle as the most frequently reported site. Most sports-related injuries are not severe enough to require inpatient hospitalization; however, they often lead to acute distress and pain which require prompt treatment with analgesics. Approximately 22% of patients who presented to the ED required pharmacotherapy for acute pain management...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/28410966/vincristine-induced-peripheral-neuropathic-pain-and-expression-of-transient-receptor-potential-vanilloid-1-in-rat
#8
Terumasa Chiba, Yusuke Oka, Hiroya Sashida, Toshie Kanbe, Kenji Abe, Iku Utsunomiya, Kyoji Taguchi
The clinical anti-cancer efficacy of vincristine is limited by the development of dose-dependent peripheral neuropathy. Up-regulation of transient receptor potential vanilloid 1 (TRPV1) is correlated with peripheral neuropathy following anti-cancer drug treatment. To analyze the contribution of TRPV1 to the development of vincristine-induced mechanical allodynia/hyperalgesia, TRPV1 expression in the rat dorsal root ganglion (DRG) was analyzed after vincristine treatment. Mechanical allodynia/hyperalgesia was tested with von Frey filaments 14 days after intraperitoneal administration of 0...
April 2017: Journal of Pharmacological Sciences
https://www.readbyqxmd.com/read/28386785/assessing-the-prognostic-features-of-a-pain-classification-system-in-advanced-cancer-patients
#9
Joseph Arthur, Kimberson Tanco, Ali Haider, Courtney Maligi, Minjeong Park, Diane Liu, Eduardo Bruera
PURPOSE: The Edmonton Classification System for Cancer Pain (ECS-CP) has been shown to predict pain management complexity based on five features: pain mechanism, incident pain, psychological distress, addictive behavior, and cognitive function. The main objective of our study was to explore the association between ECS-CP features and pain treatment outcomes among outpatients managed by a palliative care specialist-led interdisciplinary team. METHODS: Initial and follow-up clinical information of 386 eligible supportive care outpatients were retrospectively reviewed and analyzed...
April 6, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28386322/glutathione-alleviated-peripheral-neuropathy-in-oxaliplatin-treated-mice-by-removing-aluminum-from-dorsal-root-ganglia
#10
Minji Lee, Sungrae Cho, Kangsan Roh, Jisook Chae, Jin-Hee Park, Jaehyun Park, Myung-Ah Lee, Jinheung Kim, Chung-Kyoon Auh, Chang-Hwan Yeom, Sukchan Lee
Oxaliplatin, a platinum-based anti-cancer drug, induces peripheral neuropathy as a side effect and causes cold hyperalgesia in cancer patients receiving anti-cancer chemotherapy. In oxaliplatin-treated mice, aluminum was accumulated in the dorsal root ganglia (DRG), and accumulated aluminum in DRG or other organs aggravated oxaliplatin-induced neuropathic pain. To investigate whether aluminum oxalate, which is the compound of aluminum and oxaliplatin, might be the peripheral neuropathy inducer, the withdrawal responses of mice to coldness, the expression of transient receptor potential ankyrin 1 and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays in DRG were analyzed in mice administered with aluminum oxalate...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28373469/nab-paclitaxel-and-gemcitabine-in-advanced-pancreatic-cancer-the-one-year-experience-of-the-national-cancer-institute-of-naples
#11
Alessandro Ottaiano, Monica Capozzi, Chiara DE Divitiis, Claudia VON Arx, Elena DI Girolamo, Guglielmo Nasti, Ernesta Cavalcanti, Fabiana Tatangelo, Giovanni Romano, Antonio Avallone, Salvatore Tafuto
BACKGROUND: Pancreas adenocarcinoma is the sixth cause of cancer-related death worldwide with an increasing mortality in the Western countries. Recently, the association between nab-paclitaxel (nab-P) and gemcitabine (GEM) has significantly improved progression-free and overall survival. PATIENTS AND METHODS: Patients affected by metastatic pancreas adenocarcinoma were treated at the Department of Abdominal Oncology of the National Cancer Institute of Naples from July 2015 to July 2016 with nab-P at 125 mg per square meter of body-surface area followed by GEM at 1,000 mg per square meter on days 1, 8 and 15 every 4 weeks...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28306568/ketamine-for-cancer-pain-what-is-the-evidence
#12
Kelly Jonkman, Tine van de Donk, Albert Dahan
PURPOSE OF REVIEW: In this review, we assess the benefit of ketamine in the treatment of terminal cancer pain that is refractory to opioid treatment and/or complicated by neuropathy. RECENT FINDINGS: While randomized controlled trials consistently show lack of clinical efficacy of ketamine in treating cancer pain, a large number of open-label studies and case series show benefit. SUMMARY: Ketamine is an N-methyl-D-aspartate receptor antagonist that at low-dose has effective analgesic properties...
June 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28286483/long-term-effects-pathophysiological-mechanisms-and-risk-factors-of-chemotherapy-induced-peripheral-neuropathies-a-comprehensive-literature-review
#13
REVIEW
Nicolas Kerckhove, Aurore Collin, Sakahlé Condé, Carine Chaleteix, Denis Pezet, David Balayssac
Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy-induced peripheral neuropathy (CIPN). The health consequences of CIPN remain worrying as it is associated with several comorbidities and affects a specific population of patients already impacted by cancer, a strong driver for declines in older adults. The purpose of this review is to present a comprehensive overview of the long-term effects of CIPN in cancer patients and survivors...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28286117/carvedilol-prevents-functional-deficits-in-peripheral-nerve-mitochondria-of-rats-with-oxaliplatin-evoked-painful-peripheral-neuropathy
#14
Aparna Areti, Prashanth Komirishetty, Ashutosh Kumar
Oxaliplatin use as chemotherapeutic agent is frequently limited by cumulative neurotoxicity which may compromise quality of life. Reports relate this neurotoxic effect to oxidative stress and mitochondrial dysfunction in peripheral nerves and dorsal root ganglion (DRG). Carvedilol is an antihypertensive drug, has also been appreciated for its antioxidant and mitoprotective properties. Carvedilol co-treatment did not reduce the anti-tumor effects of oxaliplatin in human colon cancer cells (HT-29), but exhibited free radical scavenging activity against oxaliplatin-induced oxidative stress in neuronal cells (Neuro-2a)...
May 1, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28267067/hdac6-inhibition-effectively-reverses-chemotherapy-induced-peripheral-neuropathy
#15
Karen Krukowski, Jiacheng Ma, Olga Golonzhka, Geoffroy O Laumet, Tanuja Gutti, John H van Duzer, Ralph Mazitschek, Matthew B Jarpe, Cobi J Heijnen, Annemieke Kavelaars
Chemotherapy-induced peripheral neuropathy is one of the most common dose-limiting side effects of cancer treatment. Currently, there is no Food and Drug Administration-approved treatment available. Histone deacetylase 6 (HDAC6) is a microtubule-associated deacetylase whose function includes regulation of α-tubulin-dependent intracellular mitochondrial transport. Here, we examined the effect of HDAC6 inhibition on established cisplatin-induced peripheral neuropathy. We used a novel HDAC6 inhibitor ACY-1083, which shows 260-fold selectivity towards HDAC6 vs other HDACs...
June 2017: Pain
https://www.readbyqxmd.com/read/28257146/randomized-controlled-trial-of-neurofeedback-on-chemotherapy-induced-peripheral-neuropathy-a-pilot-study
#16
Sarah Prinsloo, Diane Novy, Larry Driver, Randall Lyle, Lois Ramondetta, Cathy Eng, Jennifer McQuade, Gabriel Lopez, Lorenzo Cohen
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant problem for cancer patients, and there are limited treatment options for this often debilitating condition. Neuromodulatory interventions could be a novel modality for patients trying to manage CIPN symptoms; however, they are not yet the standard of care. This study examined whether electroencephalogram (EEG) neurofeedback (NFB) could alleviate CIPN symptoms in survivors. METHODS: This was a randomized controlled trial with survivors assigned to an NFB group or a wait-list control (WLC) group...
March 3, 2017: Cancer
https://www.readbyqxmd.com/read/28237807/effects-of-paclitaxel-on-the-development-of-neuropathy-and-affective-behaviors-in-the-mouse
#17
Wisam Toma, S Lauren Kyte, Deniz Bagdas, Yasmin Alkhlaif, Shakir D Alsharari, Aron H Lichtman, Zhi-Jian Chen, Egidio Del Fabbro, John W Bigbee, David A Gewirtz, M Imad Damaj
Paclitaxel, one of the most commonly used cancer chemotherapeutic drugs, effectively extends the progression-free survival of breast, lung, and ovarian cancer patients. However, paclitaxel and other chemotherapy drugs elicit peripheral nerve fiber dysfunction or degeneration that leads to peripheral neuropathy in a large proportion of cancer patients. Patients receiving chemotherapy also often experience changes in mood, including anxiety and depression. These somatic and affective disorders represent major dose-limiting side effects of chemotherapy...
May 1, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28229252/pain-in-patients-with-pancreatic-cancer-prevalence-mechanisms-management-and-future-developments
#18
REVIEW
Andreas I Koulouris, Paul Banim, Andrew R Hart
Pain affects approximately 80% of patients with pancreatic cancer, with half requiring strong opioid analgesia, namely: morphine-based drugs on step three of the WHO analgesic ladder (as opposed to the weak opioids: codeine and tramadol). The presence of pain is associated with reduced survival. This article reviews the literature regarding pain: prevalence, mechanisms, pharmacological, and endoscopic treatments and identifies areas for research to develop individualized patient pain management pathways. The online literature review was conducted through: PubMed, Clinical Key, Uptodate, and NICE Evidence...
April 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28204996/incidence-of-taxane-induced-peripheral-neuropathy-receiving-treatment-and-prescription-patterns-in-patients-with-breast-cancer
#19
Su Jeong Song, Ji Min, Sung Yun Suh, Sun Hoi Jung, Hyeon Joo Hahn, Seock-Ah Im, Ju-Yeun Lee
PURPOSE: Taxane-induced peripheral neuropathy (TIPN) can affect quality of life and treatment outcomes in breast cancer patients. Despite the high incidence, treatment of PN has not been established. This study aimed to evaluate the incidence, risk factors, and prescribing pattern of TIPN receiving pharmacologic treatment in real-world practice. METHODS: We conducted a retrospective chart review of 1629 breast cancer patients who received taxanes at the Seoul National University Hospital from July 2012 to June 2014...
February 16, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28190392/pi3k-akt-pathway-a-potential-therapeutic-target-for-chronic-pain
#20
Shu-Ping Chen, Ya-Qun Zhou, Dai-Qiang Liu, Wen Zhang, Anne Manyande, Xue-Hai Guan, Yu-Ke Tian, Da-Wei Ye, Deeq Mohamed Omar
Chronic pain is among the most disabling and costly disorders, with prevalence ranging from 10% to 55%. However, current therapeutic strategies for chronic pain are unsatisfactory due to our poor understanding of its mechanisms. Thus, novel therapeutic targets need to be found in order to improve these patients' quality of life. PI3K and its downstream Akt are widely expressed in the spinal cord, particularly in the laminae I-IV of the dorsal horn, where nociceptive C and Aδ fibers of primary afferents principally terminate...
February 10, 2017: Current Pharmaceutical Design
keyword
keyword
76402
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"